The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Open accessAbstract
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These investigations have established that volumetric decline occurs initially in medial temporal lobe grey matter, following tau protein deposition, and is closely correlated to cognitive decline.”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the regional level, abnormality is evident in medial temporal lobe areas first (hippocampus and entorhinal cortex), then in lateral temporal lobe areas (mid-temporal gyrus and fusiform gyrus) and finally in frontal lobe areas (Jack Jr. et al 2010, Young et al 2014).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because measures of all biomarkers studied to date have considerable overlap with those found other types of dementia (as well the cognitively normal elderly population), it remains difficult to determine whether or not cognitive impairment is due to AD or another more dominant and concurrent process.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is Tau pathology and synapse loss that temporally correlate with cognitive impairment and precede overt neurodegeneration (Jack et al., 2010; Scheff et al., 2006; Spires-Jones and Hyman, 2014”
From Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies (2018) · cites this paper as Jack et al., 2010
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Firstly, cognitive decline is more closely correlated to neurodegeneration than tau accumulation (Jack Jr. et al 2010).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer’s disease (AD) is characterized by deposition of hallmark pathological peptides and neurodegeneration that progress across partially overlapping neuroanatomical and temporal axes1,2.”
From Integrated multimodal cell atlas of Alzheimer’s disease (2024) · cites this paper as [2]
In the citing paper
“Autosomal dominant mutations to the MAPT (tau) gene lead to neuronal tangle pathology and frontotemporal dementia but not to amyloid plaques 122,123 , suggesting that tau pathology does not induce Aβ pathology.”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [123]
In the citing paper
“Amyloid plaques appear a decade or two before clinical symptoms of AD, but it is tau pathology and synapse loss that correlate best with cognitive impairment during disease progression (Jack et al., 2010).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Jack et al., 2010
In the citing paper
“Extensive biomarker and imaging studies indicate that amyloid-β aggregation is the earliest pathological event in Alzheimer’s disease, followed at a later stage by pathological changes of tau aggregation extending beyond the limbic system to the neocortex, which correlates with brain atrophy and cognitive decline2,3.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [2]
In the citing paper
“Their timeline states that in individuals who develop AD, Aβ plaque deposition and reduced CSF Aβ occur first. Next, CSF tau levels rise. These changes manifest years before clinical signs or symptoms develop. Later on hippocampal atrophy appears, followed shortly thereafter by memory decline and eventually dementia. Full progression from Aβ changes to clinical decline takes approximately 10 to 20”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“data argue symptoms generally manifest only after plaques stop forming (Figure 5) [205, 216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“As people meeting preclinical AD criteria may remain cognitively stable for many years [205, 214], these trials will take a long time to complete.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues 18 conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations that can be detected years before psychometrically and clinically noticeable deterioration in cognition, behavior, and function.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [18]
In the citing paper
“The neuropathological changes that are quintessential for AD diagnosis—namely, the development of amyloid plaques and tau tangles—are considered to develop years before onset of the cognitive changes that characterize AD dementia [26].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I. E., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,721
Cited by
Sorted by citations
Items 801–900 of 1,077
International Work Group Criteria for the Diagnosis of Alzheimer Disease
Cummings, J. L., Dubois, B., Molinuevo, J. L., & Scheltens, P. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.01.001 · Cited by 95
Changing Concepts of Alzheimer Disease
McKhann, G. M. (2011) · JAMA · doi:10.1001/jama.2011.810 · Cited by 95
Filippi, M., & Agosta, F. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101854 · Cited by 95
Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition
Initiative, A. D. N., Tan, C. H., Fan, C. C., Mormino, E. C., Sugrue, L. P., Broce, I., Hess, C. P., Dillon, W. P., Bonham, L. W., Yokoyama, J. S., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1789-4 · Cited by 95
The Prion-Like Properties of Amyloid-β Assemblies: Implications for Alzheimer's DiseasePreprint
Walker, L. C., Schelle, J., & Jucker, M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024398 · Cited by 95
Stokin, G. B., Krell‐Roesch, J., Petersen, R. C., & Geda, Y. E. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000084 · Cited by 94
Self-citationEffect of Cognitive Reserve Markers on Alzheimer Pathologic Progression
Lo, R. Y., & Jagust, W. J. (2013) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3182900b2b · Cited by 94
Self-citationCognitive Declines Precede and Predict Functional Declines in Aging and Alzheimer’s Disease
Zahodne, L. B., Manly, J. J., MacKay‐Brandt, A., & Stern, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073645 · Cited by 94
Emerging Therapeutics for Alzheimer's Disease
Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 95
Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers
Barten, D. M., Cadelina, G. W., Hoque, N., DeCarr, L. B., Guss, V. L., Yang, L., Sankaranarayanan, S., Wes, P. D., Flynn, M. E., Meredith, J. E., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110161 · Cited by 94
How early can we diagnose Alzheimer disease (and is it sufficient)?
Petersen, R. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006088 · Cited by 94
Self-citationBron, E. E., Steketee, R. M. E., Houston, G. C., Oliver, R. A., Achterberg, H. C., Loog, M., van Swieten, J. C., Hammers, A., Niessen, W. J., Smits, M., et al. (2014) · Human Brain Mapping · doi:10.1002/hbm.22522 · Cited by 93
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Self-citationWattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions
Villeneuve, S., Reed, B., Madison, C. M., Wirth, M., Marchant, N. L., Kriger, S., Mack, W. J., Sanossian, N., DeCarli, C. S., Chui, H. C., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000550 · Cited by 93
Self-citationPlasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults
Meyer, P., Ashton, N. J., Karikari, T. K., Strikwerda‐Brown, C., Köbe, T., Gonneaud, J., Binette, A. P., Ozlen, H., Yakoub, Y., Simrén, J., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26308 · Cited by 95
Murphy, M. C., Curran, G. L., Glaser, K. J., Rossman, P. J., Huston, J., Poduslo, J. F., Jack, C. R., Felmlee, J. P., & Ehman, R. L. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2011.12.019 · Cited by 93
Self-citationBiomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Schütt, T., Toft, N., & Berendt, M. (2015) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13633 · Cited by 92
Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.
Arbor, S., LaFontaine, M., & Cumbay, M. G. (2016) · Europe PMC (PubMed Central) · Cited by 94
Pereira, J. B., Ossenkoppele, R., Palmqvist, S., Strandberg, T. O., Smith, R. A., Westman, E., & Hansson, O. (2019) · eLife · doi:10.7554/elife.50830 · Cited by 92
Dubal, D. B. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00018-7 · Cited by 92
Kerchner, G. A., & Boxer, A. L. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.493872 · Cited by 92
Frings, L., Hellwig, S., Spehl, T. S., Bormann, T., Buchert, R., Vach, W., Minkova, L., Heimbach, B., Klöppel, S., & Meyer, P. T. (2015) · Brain · doi:10.1093/brain/awv229 · Cited by 92
General anesthetic and the risk of dementia in elderly patients: current insights
Seitz, D. P., Hussain, M., Eckenhoff, R. G., & Berger, M. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s49680 · Cited by 92
GPS driving: a digital biomarker for preclinical Alzheimer disease
Bayat, S., Babulal, G. M., Schindler, S. E., Fagan, A. M., Morris, J. C., Mihailidis, A., & Roe, C. M. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00852-1 · Cited by 91
Grøntvedt, G. R., Schröder, T. N., Sando, S. B., White, L., Bråthen, G., & Doeller, C. F. (2018) · Current Biology · doi:10.1016/j.cub.2018.04.080 · Cited by 91
Hooshmand, B., Mangialasche, F., Kalpouzos, G., Solomon, A., Kåreholt, I., Smith, A. D., Refsum, H., Wang, R., Mühlmann, M., Ertl-Wagner, B. B., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0274 · Cited by 91
Exploring Biomarkers for Alzheimer’s Disease
Sharma, N. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/18828.8166 · Cited by 91
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease
Strom, A., Iaccarino, L., Edwards, L., Lesman-Segev, O. H., Soleimani-Meigooni, D. N., Pham, J., Baker, S. L., Landau, S. M., Jagust, W. J., Miller, B. L., et al. (2022) · Brain · doi:10.1093/brain/awab294 · Cited by 91
Self-citationA Novel Method for Diagnosing Alzheimer's Disease Using Deep Pyramid CNN Based on EEG Signals
Xia, W., Zhang, R., Zhang, X. L., & Usman, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2023.e14858 · Cited by 91
Executive Dysfunction in MCI: Subtype or Early Symptom
Reinvang, I., Grambaitė, R., & Espeseth, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/936272 · Cited by 91
Alzheimer's disease: a mathematical model for onset and progression
Bertsch, M., Franchi, B., Marcello, N., Tesi, M. C., & Tosin, A. (2016) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqw003 · Cited by 91
Tiepolt, S., Hesse, S., Patt, M., Luthardt, J., Schroeter, M. L., Hoffmann, K., Weise, D., Gertz, H., Sabri, O., & Barthel, H. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3353-1 · Cited by 91
TREM2‐dependent effects on microglia in Alzheimer's disease
Zhou, Y., Ulland, T. K., & Colonna, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00202 · Cited by 82
Aguirre-Acevedo, D. C., Lopera, F., Henao, E., Tirado, V., Muñoz, C., Giraldo, M., Bangdiwala, S. I., Reiman, E. M., Tariot, P. N., Langbaum, J. B., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4851 · Cited by 90
Quantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Role of amyloid beta in lipid homeostasis
Grösgen, S., Grimm, M. O. W., Frieß, P., & Hartmann, T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.002 · Cited by 90
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Hu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., McCluskey, L. F., Elman, L. B., Karlawish, J. H., Hurtig, H. I., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0723-9 · Cited by 90
Self-citationAltered Waste Disposal System in Aging and Alzheimer’s Disease: Focus on Astrocytic Aquaporin-4
Valenza, M., Facchinetti, R., Steardo, L., & Scuderi, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01656 · Cited by 90
Liu, Y., Li, H., Wang, J., Xue, Q., Yang, X., Kang, Y., Li, M., Xu, J., Li, G., Li, C., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.18777 · Cited by 90
Neuropsychiatric symptoms in the prodromal stages of dementia
Stella, F., Radanovic, M., Balthazar, M. L. F., Canineu, P. R., de Souza, L. C., & Forlenza, O. V. (2014) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000050 · Cited by 90
Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes
Gibson, G. E., Hirsch, J. A., Cirio, R. T., Jordan, B. D., Fonzetti, P., & Elder, J. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.09.001 · Cited by 90
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Leuner, K., Stockburger, C., Denzer, I., Eckert, G. P., & Müller, W. E. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394625-6.00007-6 · Cited by 89
Mosconi, L., Murray, J., Davies, M., Williams, S., Pirraglia, E., Spector, N. C., Tsui, W. H., Li, Y., Butler, T., Osorio, R. S., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004850 · Cited by 89
A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 89
Dementia in late-onset epilepsy
Johnson, E. L., Krauss, G. L., Kucharska‐Newton, A., Albert, M., Brandt, J., Walker, K. A., Yaşar, S., Knopman, D. S., Vossel, K. A., & Gottesman, R. F. (2020) · Neurology · doi:10.1212/wnl.0000000000011080 · Cited by 89
Self-citationFine Particulate Matter and Dementia Incidence in the Adult Changes in Thought Study
Shaffer, R. M., Blanco, M. N., Ge, L., Adar, S. D., Carone, M., Szpiro, A. A., Kaufman, J. D., Larson, T. V., Larson, E. B., Crane, P. K., et al. (2021) · Environmental Health Perspectives · doi:10.1289/ehp9018 · Cited by 89
Yanagisawa, D., Amatsubo, T., Morikawa, S., Taguchi, H., Urushitani, M., Shirai, N., Hirao, K., Shiino, A., Inubushi, T., & Tooyama, I. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.071 · Cited by 89
Amyloid-beta and depression in healthy older adults: A systematic review
Harrington, K., Lim, Y. Y., Gould, E., & Maruff, P. T. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414557161 · Cited by 89
Lau, K. M., Parikh, M., Harvey, D. J., Huang, C.-J., & Farias, S. T. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000818 · Cited by 89
Lao, P. J., Betthauser, T. J., Hillmer, A. T., Price, J. C., Klunk, W. E., Mihaila, I., Higgins, A. T., Bulova, P. D., Hartley, S. L., Hardison, R. M., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.013 · Cited by 89
Amyloid-β Oligomers May Impair SNARE-Mediated Exocytosis by Direct Binding to Syntaxin 1a
Yang, Y., Kim, J., Kim, H. Y., Ryoo, N., Lee, S., Kim, Y., Rhim, H., & Shin, Y.-K. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.044 · Cited by 88
Kantarci, K., Schwarz, C. G., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Zuk, S. M., Senjem, M. L., Gunter, J. L., Lowe, V., Machulda, M. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1482 · Cited by 88
Self-citationThe diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease
Miller, M. I., Younes, L., Ratnanather, J. T., Brown, T., Trinh, H., Postell, E., Lee, D. S., Wang, M.-C., Mori, S., O'Brien, R., et al. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.09.001 · Cited by 88
Current status and future role of brain PET/MRI in clinical and research settings
Werner, P., Barthel, H., Drzezga, A. E., & Sabri, O. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2970-9 · Cited by 88
Kim, M. G., Snowden, S. G., Suvitaival, T., Ali, A., Merkler, D. J., Ahmad, T., Westwood, S., Baird, A. L., Proitsi, P., Nevado‐Holgado, A. J., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.03.004 · Cited by 88
Zhao, J., Yin, F., Ji, L., Wang, C., Shi, C., Liu, X., Yang, H., Wang, X., & Kong, L. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c11064 · Cited by 88
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 88
Molecular imaging in dementia: Past, present, and future
Laforce, R. J., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
Serum albumin and beta-amyloid deposition in the human brain
Kim, J. W., Byun, M. S., Lee, J. H., Yi, D., Jeon, S. Y., Sohn, B. K., Lee, J.-Y., Shin, S. A., Kim, Y. K., Kang, K. M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010005 · Cited by 87
Alzheimer's Disease: The Downside of a Highly Evolved Parietal Lobe?
Bruner, E., & Jacobs, H. I. L. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122299 · Cited by 87
The Fornix in Mild Cognitive Impairment and Alzheimer’s Disease
Nowrangi, M. A., & Rosenberg, P. B. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00001 · Cited by 87
Military risk factors for Alzheimer's disease
Weiner, M. W., Friedl, K. E., Pacifico, A., Chapman, J. C., Jaffee, M. S., Little, D. M., Manley, G. T., McKee, A., Petersen, R. C., Pitman, R. K., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.005 · Cited by 87
Self-citationPhysical Activity and Brain Function in Older Adults at Increased Risk for Alzheimer’s Disease
Smith, J., Nielson, K. A., Woodard, J. L., Seidenberg, M., & Rao, S. M. (2013) · Brain Sciences · doi:10.3390/brainsci3010054 · Cited by 87
Liu, K., Chen, K., Li, Y., & Guo, X. (2017) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2017.00033 · Cited by 86
Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease
Sintini, I., Martin, P. R., Graff‐Radford, J., Senjem, M. L., Schwarz, C. G., Machulda, M. M., Spychalla, A. J., Drubach, D. A., Knopman, D. S., Petersen, R. C., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101823 · Cited by 87
Self-citationDevelopment of Near-Infrared Fluorescent Probes for Use in Alzheimer’s Disease Diagnosis
Yang, J., Zeng, F., Ge, Y., Peng, K., Li, X., Li, Y., & Xu, Y. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00695 · Cited by 87
The Role of Microglia in Sporadic Alzheimer’s Disease
Streit, W. J., Khoshbouei, H., & Bechmann, I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201248 · Cited by 87
Rai, H., Gupta, S., Kumar, S., Yang, J., Singh, S. K., Ran, C., & Modi, G. P. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01619 · Cited by 87
Brain Aging Among Racially and Ethnically Diverse Middle-Aged and Older Adults
Turney, I. C., Lao, P. J., Rentería, M. A., Igwe, K. C., Berroa, J., Rivera, A. M., Benavides, A., Morales, C. D., Rizvi, B. M., Schupf, N., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3919 · Cited by 87
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 88
Magnetic resonance spectroscopy in Alzheimer’s disease
Kantarci, K., & Radford, G. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s35440 · Cited by 87
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
Liu‐Seifert, H., Initiative, T. A. D. N., Siemers, E., Price, K., Han, B., Selzler, K. J., Henley, D. B., Sundell, K. L., Aisen, P. S. S., Cummings, J. L., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142508 · Cited by 90
Self-citationPrediction of Alzheimer's disease pathophysiology based on cortical thickness patterns
Hwang, J., Kim, C. M., Jeon, S., Lee, J. M., Hong, Y. J., Roh, J. H., Lee, J., Koh, J., Na, D. L., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.008 · Cited by 87
The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L. C., McRae-McKee, K., de Wolf, F., Anderson, R. M., & Initiative, T. A. D. N. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00636-z · Cited by 86
“The results support and contribute to the current understanding of the quantitative characteristics of the clinical progression of AD based on multiple clinical and biological measures [2, 26].”
InfluentialCoffee intake and decreased amyloid pathology in human brain
Kim, J. W., Byun, M. S., Yi, D., Lee, J. H., Jeon, S. Y., Jung, G., Lee, H. N., Sohn, B. K., Lee, J.-Y., Kim, Y. K., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0604-5 · Cited by 86
Understanding Epigenetics in the Neurodegeneration of Alzheimer’s Disease: SAMP8 Mouse Model
Griñán‐Ferré, C., Corpas, R., Puigoriol‐Illamola, D., Palomera‐Ávalos, V., Sanfeliu, C., & Pallàs, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170664 · Cited by 86
Mulder, S. D., Nielsen, H. M., Blankenstein, M. A., Eikelenboom, P., & Veerhuis, R. (2014) · Glia · doi:10.1002/glia.22619 · Cited by 86
Locus coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease
Ross, J. A., McGonigle, P., & Bockstaele, E. J. V. (2015) · Neurobiology of Stress · doi:10.1016/j.ynstr.2015.09.002 · Cited by 86
Dementia severity and weight loss: A comparison across eight cohorts. The 10/66 study
Albanese, E., Taylor, C. L., Siervo, M., Stewart, R. J., Prince, M. J., & Acosta, D. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.014 · Cited by 87
Clinical effect of white matter network disruption related to amyloid and small vessel disease
Kim, H. J., Im, K., Kwon, H., Lee, J.-M., Kim, C., Kim, Y. J., Jung, N.-Y., Cho, H., Ye, B. S., Noh, Y., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001705 · Cited by 85
Self-citationMartí-Juan, G., Sanroma-Guell, G., & Piella, G. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105348 · Cited by 85
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative
Weiner, M. W., & Veitch, D. P. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.007 · Cited by 85
Self-citationUnbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 85
Hopperton, K. E., Trépanier, M., Giuliano, V., & Bazinet, R. P. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0721-5 · Cited by 85
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
Papp, K. V., Buckley, R. F., Mormino, E. C., Maruff, P. T., Villemagne, V. L., Masters, C. L., Johnson, K. A., Rentz, D. M., Sperling, R. A., Amariglio, R. E., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.074 · Cited by 85
Differential vulnerability of the cerebellum in healthy ageing and Alzheimer’s disease
Gellersen, H. M., Guell, X., & Sami, S. A. K. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102605 · Cited by 85
Pereira, J. B., Janelidze, S., Strandberg, O. T., Whelan, C. D., Zetterberg, H., Blennow, K., Palmqvist, S., Stomrud, E., Mattsson, N., & Hansson, O. (2022) · Nature Aging · doi:10.1038/s43587-022-00310-z · Cited by 85
Origins of Alzheimerʼs disease
Musiek, E. S., & Holtzman, D. M. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a30f4 · Cited by 85
Curcuminoid Binds to Amyloid-β1-42 Oligomer and Fibril
Yanagisawa, D., Taguchi, H., Yamamoto, A., Shirai, N., Hirao, K., & Tooyama, I. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-102100 · Cited by 85
The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results
Aalten, P., Ramakers, I. H. G. B., Biessels, G. J., Deyn, P. P. D., Koek, H. L., Olde-Rikkert, M. G. M., Oleksik, A. M., Richard, E., Smits, L. L., Swieten, J. C. V., et al. (2014) · BMC Neurology · doi:10.1186/s12883-014-0254-4 · Cited by 85
González‐Martínez, Á., Rosado, B., Pesini, P., Suarez, M. L., Santamarina, G., García‐Belenguer, S., Villegas, A., Monleón, I., & Sarasa, M. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.02.013 · Cited by 85
Cole, G. M., & Frautschy, S. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011991 · Cited by 85
Clouston, S., Kotov, R., Pietrzak, R. H., Luft, B. J., Gonzalez, A., Richards, M., Ruggero, C. J., Spiro, A., & Bromet, E. J. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.08.001 · Cited by 85
Current trends in blood biomarker detection and imaging for Alzheimer’s disease
Hu, S., Yang, C., & Luo, H. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114278 · Cited by 84
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q.
- Affiliations
- Mayo Clinic (US)
- University of California, Berkeley (US)
- University of Pennsylvania (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Corresponding author
- Jack, Clifford R
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 9
- Issue
- 1
- Pages
- 119-128
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2819840
- OpenAlex
- W2167840686
- Cited by
- 4,806
- References
- 119
- Citations by year
- 2026: 273 · 2025: 317 · 2024: 278 · 2023: 259 · 2022: 308 · 2021: 321 · 2020: 359 · 2019: 303 · 2018: 267 · 2017: 283 · 2016: 265 · 2015: 273 · 2014: 335 · 2013: 337 · 2012: 301
- FWCI
- 127.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (AG11378)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, amyloid PET, tau protein, brain atrophy, FDG-PET, synaptic dysfunction, neurodegeneration, disease stage, biomarkers, cognitive decline
- MeSH terms
- Aging, Alzheimer Disease, Brain, Cognition Disorders, Humans, Magnetic Resonance Imaging, Models, Neurological, Time Factors, Signal Transduction, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Positron-Emission Tomography, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
